This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
HNRNPL / Heterogeneous nuclear ribonucleoprotein L · IHC design guide
Design Immunohistochemistry for HNRNPL
Plan HNRNPL staining in paraffin sections using the catalog antibody’s chromogenic IHC workflow (datasheet A03769-4). This guide covers the widespread nuclear pattern to expect and how to assess departures from it (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
HNRNPL Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining across tissues (HPA tissue IHC) | |
| Staining pattern | Widespread nuclear staining across cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A03769-4) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Cytoplasmic mRNP granules may add extranuclear signal (UniProt) | |
| Regulation | Low tissue specificity (HPA tissue RNA) | |
| Isoform / epitope | 2 isoforms; epitope differences are unreported (UniProt) |
Section 1
Recommended HNRNPL IHC & IF Protocols
The catalog antibody uses EDTA pH 8.0 heat retrieval (datasheet A03769-4). The published IHC protocols below describe paraffin sections (PMC12103590; PMC6433863).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A03769-4) |
| Fixation | Image fixative and duration unreported (datasheet A03769-4); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A03769-4); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A03769-4) |
| Primary antibody | Rabbit anti-HNRNPL, 2-5 μg/ml (datasheet A03769-4) |
| Primary incubation | Overnight at 4 °C (datasheet A03769-4) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A03769-4) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | HNRNPL-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A03769-4); neither article specifies retrieval conditions (PMC12103590; PMC6433863).
Section 2
What Is the Expected HNRNPL Staining Pattern?
HNRNPL should appear mainly in nuclei, with a nucleoplasmic pattern (UniProt P14866 localisation; HPA: ubiquitous nuclear expression). HPA reports high IHC staining in several cell populations, including appendix glandular cells, bone marrow hematopoietic cells, and caudate glial cells (HPA: High in each). Its lack of a transmembrane segment supports an intracellular interpretation (UniProt P14866 topology). HPA rates its tissue IHC pattern Supported, reflecting consistency with RNA expression data (HPA: Supported).
| Nuclear chromogen is clear in appendix glandular cells or bone marrow hematopoietic cells, with identifiable cell boundaries. | This matches the expected compartment and documented high-staining populations (HPA: ubiquitous nuclear expression; HPA: High in appendix glandular cells and bone marrow hematopoietic cells). Judge intensity against cells on the same section; a high HPA category is not a calibrated intensity threshold. |
| Signal is predominantly membranous, or forms a uniform cytoplasmic wash while nuclei remain unstained. | That distribution conflicts with the principal nucleoplasmic pattern (UniProt P14866 localisation; HPA: nucleoplasm). UniProt also records cytoplasmic mRNP granules, so a discrete cytoplasmic focus alone does not prove an artefact (UniProt P14866 localisation). Recheck the assay before assigning compartment-specific staining. |
| Strong chromogen appears chiefly outside the expected cells in an HPA-listed tissue. | Consider antibody cross-reactivity or endogenous detection activity when the mapped high-staining population lacks nuclear signal (HPA: High in the listed cells; general IHC practice). HPA describes ubiquitous nuclear expression and supplies no negative tissue group here, so staining in another cell population is not automatically false (HPA: tissue profile). |
| Brown colour spreads through stroma, lumina, or broad areas without distinct nuclear outlines. | Treat this as background until cellular localisation can be resolved (general IHC practice). Review the no-primary control, blocking and detection conditions, and chromogen development. Diffuse colour alone cannot establish HNRNPL expression, even in a tissue with documented high staining (HPA: tissue IHC profile). |
| An HPA-listed high-staining population shows no convincing nuclear signal. | Check section quality and assay performance before calling the specimen negative (general IHC practice). HPA reports high staining in, for example, adrenal glandular cells and cerebellar granular-layer cells (HPA: High in each); that reference supports a positive-control choice, but does not guarantee staining under every local assay condition. |
💡Expected HNRNPL appearanceCall a result positive when distinct nuclear chromogen is seen in HPA-documented high-staining cells, such as bronchial respiratory epithelial cells or cerebral-cortex endothelial cells (HPA: High in each; HPA: ubiquitous nuclear expression); diffuse, noncellular colour is a false-positive warning (general IHC practice).
| Tissue and cell choice | HPA reports low tissue specificity and no negative tissue group in this payload (HPA: RNA specificity; HPA: tissue IHC). Choose a documented high-staining cell population for a positive control, and compare its nuclear signal with the surrounding section rather than assuming another tissue is a true negative. |
| Antibody validation | The three listed HPA antibodies have Supported IHC status: HPA051748, HPA052661, and CAB016326 (HPA: antibody validation). This supports the reported tissue pattern; it does not establish the performance of a different catalog antibody, dilution, retrieval setting, or detection system. |
| Intracellular distribution | UniProt places HNRNPL in the nucleoplasm and also in cytoplasmic mRNP granules containing untranslated mRNAs (UniProt P14866 localisation). Because HPA describes ubiquitous nuclear IHC expression, score nuclear staining as the principal tissue result (HPA: tissue IHC profile). |
| Isoforms and epitope coverage | UniProt lists 2 isoforms and four RNA-recognition motifs across the protein (UniProt P14866 isoforms; domains). The payload does not map the catalog antibody epitope, so isoform coverage or altered recognition cannot be predicted from these annotations alone. |
| IF/ICC Q&A: where should fluorescence localise? | Predominantly to the nucleoplasm: HPA reports an enhanced nucleoplasmic location in ICC-IF (HPA: subcellular). UniProt also records cytoplasmic mRNP granules (UniProt P14866 localisation). Interpret discrete cytoplasmic foci cautiously; this IHC section makes no IF protocol recommendation. |
| Situation | Likely cause | Next action |
|---|---|---|
| No nuclear staining in a documented positive cell population. | The assay may have failed, or the chosen antibody and local conditions may not yield detectable signal (general IHC practice). HPA tissue intensity alone cannot identify which step failed (HPA: tissue IHC profile). | Verify section integrity and a same-run positive control; then review antibody dilution, antigen-retrieval setting, incubation, detection reagents, and chromogen development against the assay instructions (general IHC practice). |
| Colour is widespread but nuclei cannot be resolved. | Excess detection background, incomplete blocking, or excessive chromogen development can obscure localisation (general IHC practice). | Compare a no-primary control and reduce the background-producing step indicated by that control; keep counterstain light enough to resolve nuclei (general IHC practice). |
| Staining is mainly at tissue edges or in damaged areas. | Section artefact or uneven reagent exposure can create a misleading distribution (general IHC practice). | Inspect intact interior tissue and repeat on a sound section if needed; score HNRNPL only where nuclear outlines are interpretable (general IHC practice; HPA: ubiquitous nuclear expression). |
| A cytoplasmic pattern dominates while nuclei are blank. | The result disagrees with the main nucleoplasmic assignment (HPA: subcellular; HPA: tissue IHC). UniProt's cytoplasmic granules do not by themselves explain uniform cytoplasmic colour (UniProt P14866 localisation). | Check a documented nuclear-positive population and the no-primary control, then review antibody specificity and detection background before reporting cytoplasmic localisation (general IHC practice). |
| Unexpected cells stain strongly in a listed tissue. | Cross-reactivity or endogenous detection activity is possible (general IHC practice), although HPA's ubiquitous nuclear profile prevents treating every additional nuclear-positive cell as erroneous (HPA: tissue IHC profile). | Compare cell identity and compartment with the HPA-listed high-staining population, inspect the no-primary control, and confirm a reproducible nuclear pattern before assigning the signal to HNRNPL (general IHC practice; HPA: tissue IHC). |
| Two antibodies give different distributions. | Their HPA IHC statuses support the listed antibodies individually but do not prove identical epitope recognition or performance in every assay (HPA: antibody validation). | Compare nuclear staining in the same documented positive population under controlled conditions; review each antibody's assay instructions and avoid inferring isoform specificity without epitope data (HPA: tissue IHC; UniProt P14866 isoforms; general IHC practice). |
Experiment evidence
IHC & IF images showing HNRNPL staining
A03769-4 · IHCIHC analysis of hnRNP L/HNRNPL using anti-hnRNP L/HNRNPL antibody (A03769-4). hnRNP L/HNRNPL was detected in a paraffin-embedded section of
A03769-4 · IHCIHC analysis of hnRNP L/HNRNPL using anti-hnRNP L/HNRNPL antibody (A03769-4). hnRNP L/HNRNPL was detected in a paraffin-embedded section of
A03769-4 · IFIF analysis of hnRNP L/HNRNPL using anti-hnRNP L/HNRNPL antibody (A03769-4). hnRNP L/HNRNPL was detected in an immunocytochemical section of
A03769 · IHCIHC analysis of HNRNPL using anti-HNRNPL antibody (A03769). HNRNPL was detected in a paraffin-embedded section of human breast cancer tissue
A03769 · IHCIHC analysis of HNRNPL using anti-HNRNPL antibody (A03769). HNRNPL was detected in a paraffin-embedded section of human colorectal adenocarc
A03769 · IFIF analysis of HNRNPL using anti-HNRNPL antibody (A03769). HNRNPL was detected in an immunocytochemical section of MCF-7 cells. Enzyme antig
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000104824-HNRNPL/tissue/cerebral+cortex#imid_16488427
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000104824-HNRNPL/tissue/colon#imid_16488345
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000104824-HNRNPL/tissue/liver#imid_16488338
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000104824-HNRNPL/tissue/kidney#imid_16488339
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB016326; green = HNRNPL, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB016326; green = HNRNPL, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for HNRNPL IHC & IF
🧪Run bone marrow first: hematopoietic cells should show nuclear staining (HPA: High in bone marrow hematopoietic cells; UniProt P14866: nucleoplasm). HPA detects HNRNPL in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and expect mature enucleated erythrocytes within the positive section to lack nuclear staining (HPA: no negative tissue rows; standard IHC morphology).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: HNRNPL is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show HNRNPL in A-431, U-251MG, U2OS, CACO-2, MCF-7, NIH 3T3, with annotated localisation: Nucleoplasm (enhanced) (HPA subcellular).
Technical controls: Run a no-primary, secondary-only slide and a concentration-matched rabbit IgG isotype control alongside a target knockout sample or, if a suitable immunizing peptide is available, a peptide-block control (catalog caption: rabbit primary antibody; standard IHC controls). Quench endogenous peroxidase in bone marrow before HRP/DAB detection because hematopoietic cells can contribute peroxidase background (HPA: bone marrow hematopoietic cells; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A03769-4 paraffin-section caption does not state a fixative (catalog caption: fixative unreported). The documented IHC conditions use heat-mediated EDTA retrieval at pH 8.0, but the evidence does not establish that HNRNPL staining requires that retrieval method (catalog caption: EDTA retrieval). The supplied evidence does not establish whether frozen sections or IF are easier; for bone marrow, endogenous peroxidase may complicate chromogenic scoring (HPA: bone marrow hematopoietic cells; standard IHC practice).
HPA tissue IHC evidence for HNRNPL
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Adipocytes | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: HNRNPL is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced HNRNPL IHC Tips
HNRNPL shows widespread nuclear staining, with nucleoplasmic localisation expected (HPA tissue IHC; HPA subcellular). These questions focus on interpreting and troubleshooting chromogenic paraffin-section IHC.
How should I optimise retrieval when nuclear HNRNPL staining is weak?
Use heat-mediated antigen retrieval in EDTA at pH 8.0 as the starting condition (datasheet A03769-4). Keep heating and cooling times consistent across sections, then compare nuclear staining in matched tissue regions before changing antibody concentration (standard IHC practice). The selected paraffin-section example used 2 μg/ml primary antibody overnight at 4°C, providing a reference while retrieval is assessed (datasheet A03769-4). If staining remains weak, test a different retrieval buffer as a documented fallback on adjacent sections, alongside the EDTA condition (standard IHC practice). Judge improvement by clearer nucleoplasmic signal without increased diffuse background (HPA subcellular; standard IHC practice).
Could fixation explain variable HNRNPL staining between paraffin blocks?
The selected tissue caption identifies a paraffin-embedded section but does not state its fixative (datasheet A03769-4). Target-specific fixation sensitivity is therefore unknown from the supplied evidence; record each block’s fixative and fixation duration before attributing staining differences to HNRNPL (datasheet A03769-4; standard IHC practice). Compare adjacent sections processed with the same EDTA pH 8.0 retrieval and 2 μg/ml primary antibody overnight at 4°C (datasheet A03769-4). Include a consistently stained reference block in each run to reveal processing drift (standard IHC practice). Assess nuclear preservation and nonspecific staining alongside signal strength, since damaged morphology can make scoring unreliable (standard IHC practice).
How should I assess cytoplasmic staining when HNRNPL is expected in nuclei?
Expect predominantly nucleoplasmic staining in tissue sections (HPA tissue IHC; HPA subcellular). Cytoplasmic HNRNPL is biologically possible because it can occur in mRNP granules containing untranslated mRNAs (UniProt P14866), but a diffuse cytoplasmic DAB haze should prompt technical review (standard IHC practice). Check whether nuclei remain sharply stained and whether cytoplasmic signal persists across comparable intact cells rather than section edges (HPA subcellular; standard IHC practice). Compare adjacent sections stained with and without primary antibody to assess detection background (standard IHC practice). Do not identify cytoplasmic puncta as P bodies or stress granules solely by morphology, because the described HNRNPL granules are distinct (UniProt P14866).
Can staining differences establish which HNRNPL isoform or epitope is detected?
HNRNPL has 2 listed isoforms and 4 RNA recognition motifs, but the supplied tissue caption does not identify this antibody’s epitope (UniProt P14866; datasheet A03769-4). Treat chromogenic staining as HNRNPL signal without assigning it to one isoform until antibody documentation establishes the recognised sequence (standard IHC practice). If staining changes after retrieval, compare matched EDTA pH 8.0 sections before proposing epitope masking (datasheet A03769-4; standard IHC practice). UniProt lists phosphorylated and acetylated residues, but those annotations alone cannot establish an effect on antibody binding (UniProt P14866). An independent antibody with a documented, distinct epitope can help resolve a discordant pattern (standard IHC practice).
How can I check a surprising IHC pattern with multiplex IF?
Use IF/ICC as a separate validation experiment and verify that the chosen antibody is suitable for that application (standard IF practice). Pair HNRNPL with a validated marker of the expected cell type, such as an adipocyte marker when examining breast tissue, where adipocytes show high staining (HPA: High in breast adipocytes; standard IF practice). Choose a far-red channel and include an unstained tissue control to assess autofluorescence before interpreting weak signal (standard IF practice). Because the expected signal is nucleoplasmic, assess whether permeabilisation allows antibody access to the nuclear compartment (HPA subcellular; standard IF practice). Compare cellular distribution with chromogenic IHC while keeping each method’s controls separate (standard IHC/IF practice).
What should I change when DAB staining obscures nuclear HNRNPL?
First check whether the 10% goat-serum block and 2 μg/ml primary antibody used in the selected example were reproduced (datasheet A03769-4). Apply a peroxidase block before HRP/DAB detection and examine a section without primary antibody for endogenous-enzyme or detection background (standard IHC practice). If background remains high, titrate the primary antibody below 2 μg/ml while keeping retrieval and exposure consistent across adjacent sections (datasheet A03769-4; standard IHC practice). Review washing, tissue folds, and section drying, which can create uneven DAB deposits (standard IHC practice). Accept a change only if nucleoplasmic contrast improves without losing expected positive nuclei (HPA subcellular; standard IHC practice).
How should I score HNRNPL IHC across samples with different cellularity? ⚠ ANSWER MARKED FOR VERIFICATION
Score nuclear staining within a defined cell population and anatomical region, since HNRNPL expression is broadly nuclear across tissues (HPA tissue IHC; standard IHC practice). Record both the percentage of positive nuclei and intensity, or calculate an H-score from intensity categories 0–3 for a possible range of 0–300 (standard IHC practice). Normalise counts to the number of evaluable nuclei in that population, rather than total tissue area when cellularity differs (standard IHC practice). Keep retrieval, DAB development, imaging, and scoring thresholds consistent between samples (standard IHC practice). Report cytoplasmic staining separately so it does not inflate the nuclear measure (UniProt P14866; standard IHC practice).
Which findings distinguish true HNRNPL staining from section artefact?
A credible positive pattern shows nucleoplasmic staining in intact cells, consistent with the supported, ubiquitous nuclear tissue profile (HPA tissue IHC; HPA subcellular). Compare the cell population with the tissue context; high staining is reported in breast adipocytes and bronchial respiratory epithelial cells, among other populations (HPA tissue IHC). Staining restricted to edges, folds, or necrotic regions warrants review against adjacent well-preserved tissue (standard IHC practice). Diffuse DAB colour in a section lacking primary antibody points toward detection background, including endogenous peroxidase (standard IHC practice). Distinct cytoplasmic signal needs separate assessment because HNRNPL can occupy cytoplasmic mRNP granules (UniProt P14866).
Boster reagents
Best HNRNPL / Heterogeneous nuclear ribonucleoprotein L IHC Antibodies
Both anti-HNRNPL antibodies have IHC images from human paraffin sections and IF images from MCF-7 cells (catalog image captions). Both list Human, Mouse and Rat reactivity (catalog applications/reactivity).
Real IHC data
Anti-hnRNP L/HNRNPL Antibody ®
Cat # A03769-4
Real IHC data
Anti-HnRNP L/HNRNPL Antibody ®
Cat # A03769
A03769-4 has IHC images from human breast, colorectal, gastric and hepatocellular cancer sections, plus IF images from MCF-7 cells and human colorectal adenocarcinoma sections (A03769-4 image captions). A03769 has IHC images from human breast, colorectal, laryngeal and liver cancer sections, plus an IF image from MCF-7 cells (A03769 image captions).
Which to pick: Either SKU suits paraffin-section chromogenic IHC: each has its own breast-cancer section image showing EDTA retrieval, 2 μg/ml primary antibody and DAB detection; neither caption reports the fixative (A03769-4 and A03769 IHC image captions). For tissue IF, choose A03769-4 because its IF caption shows a human colorectal adenocarcinoma section; for cell IF/ICC, either has an MCF-7 image, with 5 μg/ml primary antibody (A03769-4 and A03769 IF image captions). Both list Human, Mouse and Rat IHC reactivity, while the supplied IHC images show human tissue only; clonality is unreported for both (catalog applications/reactivity and IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P14866 (HNRPL_HUMAN, Heterogeneous nuclear ribonucleoprotein L).
- Human Protein Atlas. HNRNPL tissue IHC expression (reliability: Supported).
- Human Protein Atlas. HNRNPL subcellular location (ICC-IF): Localized to the nucleoplasm..
- Human Protein Atlas. HNRNPL antibody validation summary (3 antibodies).
- Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L. Molecular immunology 2016 — PMC4698215.
- Unraveling Molecular Differences of Gastric Cancer by Label-Free Quantitative Proteomics Analysis. International journal of molecular sciences 2016 — PMC4730314.
- hnRNPL phase separation activates PIK3CB transcription and promotes glycolysis in ovarian cancer. Nature communications 2025 — PMC12103590.
- HnRNPL inhibits the osteogenic differentiation of PDLCs stimulated by SrCl(2) through repressing Setd2. Journal of cellular and molecular medicine 2019 — PMC6433863.
- PubMed PMID:11280764 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:15057824 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for HNRNPL (Heterogeneous nuclear ribonucleoprotein L). Expected localisation Nuclear staining across tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A03769-4). Validated IHC antibody: A03769-4 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A03769-4); 2. Fixation: Image fixative and duration unreported (datasheet A03769-4); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A03769-4); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A03769-4); 8. Primary antibody: Rabbit anti-HNRNPL, 2-5 μg/ml (datasheet A03769-4); 9. Primary incubation: Overnight at 4 °C (datasheet A03769-4). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Cytoplasmic mRNP granules may add extranuclear signal (UniProt); Isoform / epitope: 2 isoforms; epitope differences are unreported (UniProt); Regulation: Low tissue specificity (HPA tissue RNA). Evidence: UniProt P14866, HPA tissue IHC · Supported, HPA ICC-IF · nucleoplasm., Datasheet A03769-4, PMC12103590, PMC6433863. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/HNRNPL/immunohistochemistry-ihc-guide.